Elysium Health, Inc., a NYC-based life sciences company, raised $40m in Series C equity and debt financing.
The round was led by GISEV Family Office (Giuliani SpA / Royalty Pharma / HBM Healthcare / Nogra Pharma) and joined by Mayo Clinic Ventures and leading venture lender Western Technology Investment (WTI), the first debt lenders to Stemcentrx, Health IQ, and Practice Fusion. Returning investors include General Catalyst, Morningside Ventures, and Breyer Capital.
The funding will support the expansion of the company’s product portfolio and pipeline, the continued growth of its customer base, and additional human clinical trials to evaluate the safety and efficacy of new and existing products.
Led by CEO Eric Marcotulli, Elysium Health is developing clinically validated health products based on advancements in scientific research. Its pipeline now includes tests as well as clinically validated interventions.